All News

Evolving understanding of attention deficit hyperactivity disorder (ADHD) underscores the need for inclusive research and support, especially for women.

Judith Joseph, MD, MBA addressed ADHD misdiagnosis, symptoms, and effective treatments.

The accelerated approval comes after 48-week major molecular response rate data.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

Oral semaglutide had a safe and well-tolerated profile for individuals with type 2 diabetes, which is in line with those previously reported for the drug in other trials.

Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.

Pregnancy rtes show similarity across the different glucagon-like peptide-1 (GLP-1) medications that were prescribed.

The new indications include pediatric individuals with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.

The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.

Apalutamide is a hormone therapy indicated for men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Champions for Vaccine Education, Equity, and Progress reported that the majority of pharmacists believe that it is important to prioritize vaccine development and distribution.

Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.

The authors note that exercise beyond 3 times per week was not associated with a lower risk of asthma, and more research is needed to confirm this finding.

Expert discussed the potential of pelareorep, a novel immunotherapeutic agent, in treating advanced or metastatic breast cancer.

Pharmacists play a key role when it comes to medication substitution, especially for interchangeable biosimilars where allowed by state law.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Nearly 19,000 independent pharmacies continue to work across the country, with more than 200,000 employees and millions of patients.

Nationally, 7 million women live in maternal health deserts, defined as counties with limited or no available obstetric care.

Changing the way pharmacists and pharmacy staff think about themselves is key, although providers, payers, and patients must also change how they view the value of pharmacy services.

With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.

In postmenopausal women, the gel can reduce moderate to severe hot flashes as well as menopausal changes and symptoms.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Orlynvah is approved for uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.